Method Of Synthesizing Watermelon Seed Nanoparticles

Abstract

The watermelon seed nanoparticles may be synthesized by dissolving powdered watermelon seeds in a solvent to produce a first mixture, adding the first mixture dropwise to boiling water under ultrasonic conditions to produce a second mixture, sonicating the second mixture and drying the second mixture to produce watermelon seed nanoparticles. In an embodiment, the watermelon seeds may be Citrullus lanatus seeds. In an embodiment, the watermelon seed nanoparticles may be included in a pharmaceutical composition, such as an antimicrobial or anti-cancer composition.

Description

BACKGROUND

1. Field

[0001] The disclosure of the present patent application relates to nanotechnology, and particularly to a method of producing watermelon seed nanoparticles and their use in pharmaceutical compositions.

2. Description of the Related Art

[0002] In materials science, nanomaterials have demonstrated unique size and morphology based characteristics. Nanotechnology is an emerging field demonstrating significant potential for the development of new medicines. Nanomaterials have demonstrated improved oral bioavailability and solubility. The most common methods of producing nanoparticles are chemical or mechanical, including ball milling, thermal quenching, precipitation techniques, and vapor deposition. However, these methods are often costly, and may result in toxic byproducts.

[0003] Biological approaches for synthesizing nanoparticles can avoid many of the disadvantages associated with the chemical or mechanical synthesis methods.

[0004] Thus, a method of synthesizing watermelon seed nanoparticles are desired.

SUMMARY

[0005] Watermelon seed nanoparticles may be synthesized by dissolving powdered watermelon seeds in a solvent to produce a first mixture, adding the first mixture dropwise to boiling water under ultrasonic conditions to produce a second mixture, sonicating the second mixture and drying the second mixture to produce the watermelon seed nanoparticles.

[0006] An embodiment of the present subject matter is directed to a method of synthesizing watermelon seed nanoparticles.

[0007] An embodiment of the present subject matter is directed to a pharmaceutical composition comprising the watermelon seed nanoparticles and a pharmaceutically acceptable carrier.

[0008] An embodiment of the present subject matter is directed to a method of making a pharmaceutical composition including mixing the watermelon seed nanoparticles with a pharmaceutically acceptable carrier.

[0009] These and other features of the present disclosure will become readily apparent upon further review of the following specification and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] FIG. 1 depicts a zeta sizer spectrum of the watermelon seed nanoparticles.

[0011] FIG. 2A depicts a transmission electron micrograph of the watermelon seed nanoparticles.

[0012] FIG. 2B depicts a transmission electron micrograph of the watermelon seed nanoparticles.

[0013] FIG. 3 depicts a graph of the cytotoxic effect of the watermelon seed nanoparticles on HCT-116 cells.

[0014] FIG. 4 depicts a graph of the cytotoxic effect of the watermelon seed nanoparticles on MCF-7 cells.

[0015] Similar reference characters denote corresponding features consistently throughout the attached drawings.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] A method of synthesizing watermelon (Citrullus lanatus) seed nanoparticles may include dissolving powdered watermelon seeds in a solvent to produce a first mixture, adding the first mixture dropwise to boiling water under ultrasonic conditions to produce a second mixture, sonicating the second mixture and drying the second mixture to produce watermelon seed nanoparticles.

[0017] Citrullus lanatus is an herbaceous creeping watermelon plant originating from the Kalahari Desert of southern Africa. A single Citrullus lanatus plant may produce an average of 3 to 5 fruits weighing 3 to 8 kg each. The watermelon seeds of the Citrullus lanatus are a potential source of many desirable trace components, including but not limited to zinc, magnesium, calcium, protein, B vitamins, fats, and other minerals.

[0018] As used herein, the term "about," when used to modify a numerical value, means within ten percent of that numerical value.

[0019] In an embodiment, the powdered watermelon seeds may be synthesized by obtaining Citrullus lanatus seeds, washing the seeds with distilled water, drying the seeds, grinding the dried seeds, and separating the watermelon seed powder using a sieve of 0.355 mm.

[0020] In an embodiment, the method of synthesizing watermelon seed nanoparticles may include dissolving the powdered watermelon seeds in methanol to produce the first mixture. For example, about 500 mg of the powdered watermelon seeds can be dissolved in about 10 ml of methanol to produce the first mixture. The first mixture can be added dropwise to about 40 ml of boiling water with a flow rate of about 0.1 ml/min. to about 0.3 ml/min. in about 10 minutes under ultrasonic conditions to produce the second mixture. The second mixture can be sonicated for about 20 minutes.

[0021] An embodiment of the present subject matter is directed to watermelon seed nanoparticles. The watermelon seed nanoparticles may have an average diameter of 215 mu. The watermelon seed nanoparticles may be spherical and well dispersed. The watermelon seed nanoparticles may have antimicrobial activity, including but not limited to anti-fungal activity, anti-gram-positive bacterial activity, and anti-gram-negative bacterial activity. The watermelon seed nanoparticles may also have anti-cancer activity. In an embodiment, the watermelon seed nanoparticles may kill cancer cells, including but not limited to colon cancer cells and breast cancer cells.

[0022] An embodiment of the present subject matter is directed to a pharmaceutical composition comprising the watermelon seed nanoparticles and a pharmaceutically acceptable carrier.

[0023] An embodiment of the present subject matter is directed to a method of making a pharmaceutical composition including mixing the watermelon seed nanoparticles with a pharmaceutically acceptable carrier. For example, the method of making a pharmaceutical composition can include mixing the watermelon seed nanoparticles under sterile conditions with a pharmaceutically acceptable carrier with preservatives, buffers, and/or propellants to create the pharmaceutical composition.

[0024] An embodiment of the present subject matter is directed to a pharmaceutical composition including the watermelon seed nanoparticles. To prepare the pharmaceutical composition, the watermelon seed nanoparticles, as the active ingredient, are intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques. Carriers are inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorings, sweeteners, preservatives, dyes, and coatings. In preparing compositions in oral dosage form, any of the pharmaceutical carriers known in the art may be employed. For example, for liquid oral preparations, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like. Further, for solid oral preparations, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like.

[0025] The present compositions can be in unit dosage forms such as tablets, pills, capsules, powders, granules, ointments, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampules, auto-injector devices or suppositories, for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. The active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier and, if required, any needed preservatives, buffers, or propellants. The composition can be presented in a form suitable for daily, weekly, or monthly administration. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful, suppository and the like, an amount of the active ingredient necessary to deliver an effective dose.

[0026] The following examples illustrate the present teachings.

Example 1

Synthesis of Watermelon Seed Nanoparticles

[0027] Watermelon seed nanoparticles were synthesized as follows. Watermelon seeds of Citrullus lanatus were obtained from a market in Riyadh, Saudi Arabia. The watermelon seeds were washed with distilled water and dried. The dried watermelon seeds were ground to produce watermelon seed powder, and the watermelon seed powder was filtered through a sieve of 0.355 mm and stored for later use. 500 mg of the watermelon seed powder was then dissolved in 10 ml methanol to form a first mixture. The first mixture was then added dropwise to 40 ml of boiling water, under ultrasonic conditions at a flow rate of 0.1-0.3 ml/min over 10 minutes, to form a second mixture. The second mixture was sonicated for 20 minutes, stirred for a further 15 minutes, and dried, producing the watermelon seed nanoparticles.

Example 2

Characterization of Watermelon Seed Nanoparticles

[0028] Watermelon seed nanoparticles synthesized according to Example 1 were characterized as follows. The watermelon seed nanoparticles were analyzed in a zeta-sizer, revealing an average diameter of 215 nm and a polydispersity index of 0.111. The nanoparticles are colloidal, display long term stability, and have a high dispersity. (See FIG. 1 and Table 1) Transmission electron micrographs demonstrated that the watermelon seed nanoparticles are spherical to round in shape and well dispersed, without agglomeration (See FIGS. 2A-2B)

TABLE-US-00001 TABLE 1 Zeta-sizer characterization of watermelon seed nanoparticles Z-avg Size % St Dev (d nm) 215.0 (d nm) Intensity (d nm) Pdl 0.111 Peak 1 238.2 100.0 80.15 Intercept 0.942 Peak 2 0.000 0.0 0.000 Quality Good Peak 3 0.000 0.0 0.000

Example 3

Antimicrobial Activity of the Watermelon Seed Nanoparticles

[0029] Watermelon seed nanoparticles synthesized according to Example 1 were tested for antimicrobial activity against gram negative bacteria, gram positive bacteria, and fungi. Zone of inhibition studies were performed, the results of which are summarized in Table 2 (displaying mean zone of inhibition in mm.+-.standard deviation beyond well diameter of 6 mm). Testing used the diffusion agar technique with 6.0 mm well diameter and administration of 100 .mu.g of the watermelon seed nanoparticles.

TABLE-US-00002 TABLE 2 Antimicrobial Activity of the Watermelon Seed Nanoparticles Micro-organism Nanoparticles Control FUNGI Amphotericin B Aspergillus fumigatus (RCMB 02567) 20.7 .+-. 1.5 21.7 .+-. 1.5 Gram Positive Bacteria Ampicillin Streptococcus pneumoniae (RCMB 16.7 .+-. 1.5 21.0 .+-. 1.0 010011) Bacillus subtilis (RCMB 010068) 22.7 .+-. 1.5 31.3 .+-. 1.5 Gram Negative Bacteria Gentamicin Escherichia coli (RCMB 010054) 22.0 .+-. 1.0 20.3 .+-. 0.58

Example 4

Cytotoxic Activity of the Watermelon Seed Nanoparticles Against Cancerous Cells

[0030] Watermelon seed nanoparticles synthesized according to Example 1 were tested for cytotoxicity against colon cancer cells (HCT-116) and breast cancer cells (MCF-7). The results of these tests are presented in Tables 3-4 and FIGS. 3-4. The watermelon seed nanoparticles displayed inhibitory activity against HCT-116 cells with an IC.sub.50 of 40.1 .mu.g. The watermelon seed nanoparticles also displayed inhibitory activity against MCF-7 cells with an IC.sub.50 of 4.36 .mu.g.

TABLE-US-00003 TABLE 3 Cytotoxic Activity of Watermelon Seed Nanoparticles Against HCT-116 Cells. Conc. Viability % (Replicates) Inhibition Std. Dev. (.mu.g) 1st 2nd 3rd Mean % (.+-.) 100 17.94 18.25 21.39 19.19 80.81 1.91 50 39.72 36.88 35.16 37.25 62.75 2.30 25 72.34 67.52 68.47 69.44 30.56 2.55 12.5 81.63 85.91 82.65 83.40 16.60 2.24 6.25 95.16 97.62 94.28 95.69 4.31 1.73 3.125 98.73 100 97.63 98.79 1.21 1.19 0 100 100 100 100 0.00

TABLE-US-00004 TABLE 4 Cytotoxic Activity of Watermelon Seed Nanoparticles Against MCF-7 Cells. Conc. Viability % (Replicates) Inhibition Std. Dev. (.mu.g) 1st 2nd 3rd Mean % (.+-.) 100 21.87 19.93 24.51 22.10 77.90 2.30 50 39.56 43.87 40.92 41.45 58.55 2.20 25 74.18 70.63 79.14 74.65 25.35 4.27 12.5 89.65 87.18 91.78 89.54 10.46 2.30 6.25 97.52 96.64 98.16 97.44 2.56 0.76 3.125 100 99.71 100 99.90 0.10 0.17 0 100 100 100 100 0.00

[0031] It is to be understood that the method of synthesizing watermelon seed nanoparticles are not limited to the specific embodiments described above, but encompass any and all embodiments within the scope of the generic language of the following claims enabled by the embodiments described herein, or otherwise shown in the drawings or described above in terms sufficient to enable one of ordinary skill in the art to make and use the claimed subject matter.

Claims

1-16. (canceled)

17. A pharmaceutical composition comprising watermelon seed nanoparticles.

18. The pharmaceutical composition of claim 17, wherein the watermelon seed nanoparticles further comprise Citrullus lanatus seed nanoparticles.

19. The pharmaceutical composition of claim 17, wherein the watermelon seed nanoparticles have an average diameter of 215 nm.

20. The pharmaceutical composition of claim 17, further comprising a pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 17, wherein the watermelon seed nanoparticles are cytotoxic against cancer cells.

22. The pharmaceutical composition of claim 21, wherein the cancer cells are selected from the group consisting of colon cancer cells and breast cancer cells.

23. The pharmaceutical composition of claim 17, wherein the watermelon seed nanoparticles have antimicrobial activity.

24. The pharmaceutical composition of claim 23, wherein the watermelon seed nanoparticles have antimicrobial activity against microbes selected from the group consisting of fungi, gram positive bacteria, and gram negative bacteria.

Images